Cutler Investment Counsel LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 58,763 shares of the company’s stock after buying an additional 359 shares during the quarter. Johnson & Johnson accounts for about 1.4% of Cutler Investment Counsel LLC’s portfolio, making the stock its 29th largest holding. Cutler Investment Counsel LLC’s holdings in Johnson & Johnson were worth $9,108,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares in the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $4,609,399,000. Morgan Stanley increased its holdings in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Johnson & Johnson by 15.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after acquiring an additional 3,849,148 shares in the last quarter. Finally, Savant Capital LLC increased its holdings in Johnson & Johnson by 8,568.8% in the 4th quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after acquiring an additional 3,588,251 shares in the last quarter. 68.40% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Up 0.0 %
Shares of JNJ stock opened at $164.31 on Wednesday. The company’s 50-day moving average price is $166.68 and its 200-day moving average price is $161.50. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The stock has a market cap of $427.04 billion, a price-to-earnings ratio of 33.26, a PEG ratio of 2.76 and a beta of 0.54. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be given a $1.19 dividend. The ex-dividend date is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.90%. Johnson & Johnson’s payout ratio is currently 96.36%.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock valued at $7,928,856 over the last 90 days. 0.20% of the stock is owned by insiders.
Analyst Ratings Changes
Several equities research analysts recently commented on the stock. Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Citigroup assumed coverage on shares of Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Tuesday, August 22nd. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $187.00 target price on shares of Johnson & Johnson in a research note on Friday, July 21st. Eight investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $171.80.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Inexpensive Mid Cap Tech Stocks With Good Growth Prospects
- Investing In Preferred Stock vs. Common Stock
- 3 Reasons the Dick’s Sporting Goods Selloff Is a Steal
- Why Invest in High-Yield Dividend Stocks?
- Foot Locker Stock Takes a Big Hit…Is It a Retail Bargain?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
